Translational Research Institute
The Translational Research Institute (TRI) brings 4 of the country’s pinnacle research facilities together to improve and accelerate medical research and translate that research into greater palliative care.
The TRI allows biopharmaceuticals and treatments to be discovered, produced, clinically tested and manufactured in 1 location.
It combines academic medicine and translational research, in order to minimise the time between a laboratory discovery and its effective application in the clinic and the community.
The TRI focuses on a wide range of health and medical research areas including:
- cervical cancer
- prostate cancer
- breast cancer
- liver and kidney disease
Co-located at TRI is the nation's first fully dedicated GMP contract manufacturing facility for mammalian cell-based biotherapeutics. The facility is operated by Patheon Thermo-Fischer Scientific, a global life sciences and materials sciences company with 26 manufacturing sites located across 11 countries.
The Brisbane operation provides clinical manufacturing, analytical services, process validation, technical transfer, commercialisation strategies and biomanufacturing solutions.
The TRI is a joint venture between the University of Queensland's Diamantina Institute, Queensland University of Technology's Institute of Health and Biomedical Innovation, Mater Research and the Princess Alexandra Hospital’s Centres for Health Research.